Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Pithampur Unit-3 facility. The USFDA had conducted an inspection at the said facility from July 7 to July 17, 2025. The facility manufactures metered dose inhalers, dry powder inhalers, topical formulations, and nasal solutions.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
